The global COPD and asthma devices market is expected to reach $51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027.

Chronic obstructive pulmonary disease (COPD) and asthma devices, also known as pulmonary drug delivery devices, are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. COPD and asthma have significant shares in the global respiratory diseases market. According to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.

The major factors that drive the market growth are increase in concerns of respiratory diseases, such as asthma and emphysema, and rise in incidences of respiratory diseases caused due to cigarette consumption. Furthermore, increase in healthcare expenditure, growth in use of automation in the healthcare industry, and rapid adoption of advanced medical solutions also boost the market growth. Currently, most of healthcare practitioners and pulmonary diseases specialists prefer a combination of a drug and a device, for instance, inhaler and nebulizer, owing to its fast and effective outcome. However, the factors such as high cost associated with nebulizers, side effects occurring due to excessive dosage, and lack of awareness regarding the drug inhalation are expected to restrain the growth of the market. On the contrary, introduction of smart inhaler drives the opportunity for the growth of COPD and asthma devices market in near future.

The global COPD and asthma devices market is segmented on the basis of product type, indication, distributional channel, and region. Based on the device type, the market is segmented into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on indication, the market is divided into asthma and COPD. Based on distribution channel, it is segregated into retail pharmacies, online pharmacies, and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of respective countries.

The leading players profiled in this report include Aerogen, Inc., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, 3M COMPANY, GF Health Products, GlaxoSmithKline Plc, Koninklijke Philips N.V., Novartis AG, PARI Medical Holding GMBH, and Smith's Group Plc.

KEY BENEFITS FOR STAKEHOLDERS

- This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Key Market Segments

By Product Type
- Inhalers
o Drug Powder Inhalers (DPIs)
o Metered Dose Inhalers (MDIs)
o Soft Mist Inhalers (SMIs)
- Nebulizers
o Compressor Nebulizers
o Ultrasonic Nebulizers
o Mesh Nebulizers
By Indication
o Asthma
o COPD
By Distribution Channel
o Retail Pharmacies
o Hospitals
o Online Pharmacies
- By Region
o North America
- U.S.
- Canada
- Mexico
o Europe
- Germany
- France
- UK
- Italy
- Russia
- Rest of Europe
o Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
o Middle East
- Saudi Arabia
- Brazil
- Argentina
- Colombia
- Turkey
- Rest of LAMEA
List of key players profiled in the report
- Aerogen, Inc.
- AstraZeneca PLC
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- 3M COMPANY
- GF Health Products
- GlaxoSmithKline Plc
- Koninklijke Philips N.V.
- Novartis AG
- PARI Medical Holding GMBH
- Smith's Group Plc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Lincare Holdings Inc
- Allied Healthcare Products Inc
- Sunovion Pharmaceuticals Inc